دورية أكاديمية
Immune Checkpoint Inhibitor-related Guillain-Barré Syndrome: A Case Series and Review of the Literature.
| العنوان: | Immune Checkpoint Inhibitor-related Guillain-Barré Syndrome: A Case Series and Review of the Literature. |
|---|---|
| المؤلفون: | Janssen JBE; Departments of Medical Oncology., Leow TYS; Departments of Medical Oncology., Herbschleb KH; Department of Internal Medicine, St. Antonius Ziekenhuis, Nieuwegein, The Netherlands., Gijtenbeek JMM; Neurology, Radboud University Medical Center., Boers-Sonderen MJ; Departments of Medical Oncology., Gerritsen WR; Departments of Medical Oncology.; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen., Westdorp H; Departments of Medical Oncology.; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen. |
| المصدر: | Journal of immunotherapy (Hagerstown, Md. : 1997) [J Immunother] 2021 Sep 01; Vol. 44 (7), pp. 276-282. |
| نوع المنشور: | Case Reports; Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9706083 Publication Model: Print Cited Medium: Internet ISSN: 1537-4513 (Electronic) Linking ISSN: 15249557 NLM ISO Abbreviation: J Immunother Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Hagerstown, MD : Lippincott Williams & Wilkins Original Publication: Hagerstown, MD : Lippincott-Raven, c1997- |
| مواضيع طبية MeSH: | Antibodies, Monoclonal, Humanized/*adverse effects , Guillain-Barre Syndrome/*chemically induced , Immune Checkpoint Inhibitors/*adverse effects , Nivolumab/*adverse effects, Aged ; Fatal Outcome ; Guillain-Barre Syndrome/drug therapy ; Humans ; Immunoglobulins, Intravenous/therapeutic use ; Male ; Melanoma/drug therapy ; Middle Aged ; Prednisolone/therapeutic use ; Prostatic Neoplasms, Castration-Resistant/drug therapy |
| مستخلص: | Immune checkpoint inhibitors (ICIs) have been approved for the treatment of various malignancies with promising clinical outcomes. Treatment can, however, be accompanied by serious immune-related adverse events. Neurological adverse events like Guillain-Barré syndrome (GBS) are rare but potentially life-threatening. We present 3 cases of ICI-related GBS; review cases described in current literature, and discuss treatment strategies. Three patients developed GBS after ICI treatment. The first case with pembrolizumab had a fatal outcome despite treatment with multiple regimens, including steroids and intravenous immunoglobulin (IVIg). The other 2 cases with nivolumab-induced and pembrolizumab-induced GBS, respectively, responded well to treatment with IVIg and steroids. In the current literature, a total of 31 other cases were found. Treatment for ICI-related GBS mostly consisted of concurrent IVIg and steroids (44%), which led to clinical improvement in 73%. Most patients recovered with remaining symptoms (68%), while 10 patients developed respiratory failure (29%) and 6 patients (18%) died. ICI-related GBS should be suspected in patients on ICI treatment who develop subacute progressive weakness of the limbs, sensory loss, and areflexia. On the basis of the guidelines recommendations and our review of the literature, we advise first-line therapy with concurrent IVIg 0.4 g/kg/d for 5 days and prednisolone 1-2 mg/kg/d. Discontinuation of immunotherapy after ICI-related GBS is advised. (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.) |
| References: | Garcia CR, Cox JN, Villano JL. Myasthenia gravis and Guillain-Barré syndrome adverse events with immune checkpoint inhibitors. J Clin Oncol. 2018;36 (suppl):37. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barre syndrome. Lancet. 2016;388:717–727. Gu Y, Menzies AM, Long GV, et al. Immune mediated neuropathy following checkpoint immunotherapy. J Clin Neurosci. 2017;45:14–17. Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol. 2011;22:991–993. Bot I, Blank CU, Boogerd W, et al. Neurological immune-related adverse events of ipilimumab. Pract Neurol. 2013;13:278–280. Gaudy-Marqueste C, Monestier S, Franques J, et al. A severe case of ipilimumab-induced guillain-barre syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunotherapy. 2013;36:77–78. Kelly Wu W, Broman KK, Brownie ER, et al. Ipilimumab-induced Guillain-Barre syndrome presenting as dysautonomia: an unusual presentation of a rare complication of immunotherapy. J Immunotherapy. 2017;40:196–199. Patel RJ, Liu MA, Amaraneni A, et al. Rare side effect of adjuvant ipilimumab after surgical resection of melanoma: Guillain-Barre syndrome. BMJ Case Rep. 2017;2017:bcr2017221318. Youssef MN, Harrison RA, Woodman K, et al. Neurologic complications in cancer patients exposed to checkpoint inhibitors. American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, Calif; 2018. Spain L, Walls G, Julve M, et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol. 2017;28:377–385. Garcia CA, El-Ali A, Rath TJ, et al. Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases. J Immunother Cancer. 2018;6:83. Gravbrot N, Scherer K, Sundararajan S. Safe transition to pembrolizumab following ipilimumab-induced Guillain-Barré syndrome: a case report and review of the literature. Case Rep Oncol Med. 2019;2019:5490707. de Maleissye MF, Nicolas G, Saiag P. Pembrolizumab-induced demyelinating polyradiculoneuropathy. N Engl J Med. 2016;375:296–297. Manam R, Martin JL, Gross JA, et al. Case reports of pembrolizumab-induced acute inflammatory demyelinating polyneuropathy. Cureus. 2018;10:e3371. Ong S, Chapman J, Young G, et al. Guillain-Barre-like syndrome during pembrolizumab treatment. Muscle Nerve. 2018. doi: 10.1002/mus.26101. (PMID: 10.1002/mus.26101) Yost MD, Chou CZ, Botha H, et al. Facial diplegia after pembrolizumab treatment. Muscle Nerve. 2017;56:e20–e21. Muralikrishnan S, Ronan LK, Coker S, et al. Treatment considerations for patients with unresectable metastatic melanoma who develop pembrolizumab-induced Guillain-Barré toxicity: a case report. Case Rep Oncol. 2020;13:43–48. Han C, Ma JA, Zhang Y, et al. Guillain-Barre syndrome induced by pembrolizumab and sunitinib: a case report. Mol Clin Oncol. 2020;13:38–42. Tanaka R, Maruyama H, Tomidokoro Y, et al. Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barre syndrome: a case report. Japanese J Clin Oncol. 2016;46:875–878. Fukumoto Y, Kuwahara M, Kawai S, et al. Acute demyelinating polyneuropathy induced by nivolumab. J Neurol Neurosurg Psychiatry. 2018;89:435–437. Schneiderbauer R, Schneiderbauer M, Wick W, et al. PD-1 Antibody-induced Guillain-Barre syndrome in a patient with metastatic melanoma. Acta Dermato-venereol. 2017;97:395–396. Nukui T, Nakayama Y, Yamamoto M, et al. Nivolumab-induced acute demyelinating polyradiculoneuropathy mimicking Guillain-Barre syndrome. J Neurol Sci. 2018;390:115–116. Johnson DB, Wallender EK, Cohen DN, et al. Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunol Res. 2013;1:373–377. Jacob A, Unnikrishnan DC, Mathew A, et al. A case of fatal Guillain-Barre syndrome from anti-PD1 monoclonal antibody use. J Cancer Res Clin Oncol. 2016;142:1869–1870. Kyriazoglou A, Liontos M, Papadopoulos C, et al. Guillain-Barre syndrome related to nivolumab: case report of a patient with urothelial cancer and review of the literature. Clin Genitour Cancer. 2019;17:e360–e364. Thapa B, Khalid S, Vakili R, et al. Nivolumab-associated Guillain-Barre syndrome in a patient with non-small-cell lung cancer. Am J Therapeut. 2018;25:e761–e763. Mazzaschi G, Bordi P, Fioretzaki R, et al. Nivolumab-induced Guillain-Barre syndrome coupled with remarkable disease response in a case of heavily pretreated lung adenocarcinoma. Clin Lung Cancer. 2020;21:e65–e73. Yuen C, Kamson D, Soliven B, et al. Severe relapse of vaccine-induced Guillain-Barre syndrome after treatment with nivolumab. J Clini Neuro Dis. 2019;20:194–199. Supakornnumporn S, Katirji B. Guillain-Barre syndrome triggered by immune checkpoint inhibitors: a case report and literature review. J Clin Neuro Dis. 2017;19:80–83. Wilson R, Menassa DA, Davies AJ, et al. Seronegative antibody-mediated neurology after immune checkpoint inhibitors. Ann Clin Transl Neurol. 2018;5:640–645. McNeill CJ, Fehmi J, Gladwin J, et al. A rare case of miller fisher variant of Guillain-Barre syndrome (GBS) induced by a checkpoint inhibitor. BMJ Case Rep. 2019;12:e229443. Pomerantz M, Lichtenstein DA, Niesvizky-Kogan I, et al. Nivolumab and ipilimumab-induced acute inflammatory demyelinating polyradiculoneuropathy: a case report. J Immun. 2019;42:348–349. Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv119–iv142. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714–1768. Buchwald B, Ahangari R, Weishaupt A, et al. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome. Ann Neurol. 2002;51:673–680. Jacobs BC, O’Hanlon GM, Bullens RW, et al. Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain. 2003;126:2220–2234. Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther. 2004;102:177–193. Franchimont D, Kino T, Galon J, et al. Glucocorticoids and inflammation revisited: the state of the art. NIH clinical staff conference. Neuroimmunomodulation. 2002;10:247–260. Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2019. J Natl Compr Canc Netw. 2019;17:255–289. |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal, Humanized) 0 (Immune Checkpoint Inhibitors) 0 (Immunoglobulins, Intravenous) 31YO63LBSN (Nivolumab) 9PHQ9Y1OLM (Prednisolone) DPT0O3T46P (pembrolizumab) |
| تواريخ الأحداث: | Date Created: 20210324 Date Completed: 20220321 Latest Revision: 20230901 |
| رمز التحديث: | 20230902 |
| DOI: | 10.1097/CJI.0000000000000364 |
| PMID: | 33758147 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1537-4513 |
|---|---|
| DOI: | 10.1097/CJI.0000000000000364 |